Name: TRAVERE THERAPEUTICS INC (TVTX) Stock
Brand: TRAVERE THERAPEUTICS INC
Rating: 7 (3 reviews)

TVTX Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Chartmill

Travere Therapeutics Inc (NASDAQ:TVTX) Screened as a High Growth Momentum Stock with Strong Technical Setup

14 days ago - By: Investor's Business Daily - Mentions: LGND OABI RPRX MRK ...

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year

14 days ago - By: The Motley Fool - Mentions: PTCT SUPN INCY NBIX

This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why

14 days ago - By: The Motley Fool - Mentions: PTCT SUPN INCY NBIX

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally

21 days ago - By: Travere Therapeutics, Inc.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

25 days ago - By: Travere Therapeutics, Inc.

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

a month ago - By: Travere Therapeutics, Inc.

Travere Therapeutics to Participate at Upcoming Investor Conferences

a month ago - By: Investor's Business Daily

Top 2% Travere Looks To Top Buy Zone After Screaming Up Another Beat

a month ago - By: Travere Therapeutics, Inc.

Travere Therapeutics Reports Third Quarter 2025 Financial Results

a month ago - By: Benzinga - Mentions: IR CDP ENTG BUD ...

Earnings Scheduled For October 30, 2025

a month ago - By: Travere Therapeutics, Inc.

Travere Therapeutics to Report Third Quarter 2025 Financial Results

2 months ago - By: Travere Therapeutics, Inc.

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025

2 months ago - By: Travere Therapeutics, Inc.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Travere Therapeutics, Inc.

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

2 months ago - By: Vifor International AG (CSL Vifor)

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

2 months ago - By: Benzinga

The Analyst Verdict: Travere Therapeutics In The Eyes Of 9 Experts

3 months ago - By: Travere Therapeutics, Inc.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Investor's Business Daily

Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High

3 months ago - By: Stocktwits - Mentions: VTI IWM

Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application

3 months ago - By: Travere Therapeutics, Inc.

Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS

3 months ago - By: Travere Therapeutics, Inc.

Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism

3 months ago - By: Investor's Business Daily

Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch

3 months ago - By: Travere Therapeutics, Inc.

TRAVERE THERAPEUTICS INC (TVTX) Stock News

TVTX Latest News, Press Relases and Analysis

Travere Therapeutics Inc (NASDAQ:TVTX) Screened as a High Growth Momentum Stock with Strong Technical Setup

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year

This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

Travere Therapeutics to Participate at Upcoming Investor Conferences

Top 2% Travere Looks To Top Buy Zone After Screaming Up Another Beat

Travere Therapeutics Reports Third Quarter 2025 Financial Results

Earnings Scheduled For October 30, 2025

Travere Therapeutics to Report Third Quarter 2025 Financial Results

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

The Analyst Verdict: Travere Therapeutics In The Eyes Of 9 Experts

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High

Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application

Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS

Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism

Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch

Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy